Kaveri Pohlman

Q: What is Kaveri Pohlman's success rate?

Kaveri Pohlman currently has a success rate of 66.03456934002398.

Q: What is the average return of Kaveri Pohlman's calls?

Their stock ratings have generated an average return of 58.82224329599291.

Clear Street | Healthcare

Kaveri Pohlman is an analyst from Clear Street specializing in the Healthcare sector. Ranked #391 out of 4580 analysts, they have issued 17 stock ratings with a success rate of 66.03% and an average return of 58.82%.

With 17 ratings to date, Kaveri Pohlman is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 66.03% and an average return of 58.82%, highlighting promising potential as their track record develops further.

#391

Out of 4580

Total Ratings

+66.03%

Success Rate

+58.82%

Average Return

Recent Ratings Analysis

EVMN

Buy

Mar 18, 2026

Target

$53.00

Current

$25.03

Performance

—

Kaveri Pohlman rated EVMN as Buy on Mar 18, 2026, setting a price target of 53. Shares have remained stable near 25.03, leaving the 53 target still in play.

MLTX

Buy

Mar 11, 2026

Target

$70.00

Current

$16.77

Performance

-6.00%

On Mar 11, 2026, MLTX was given a Buy rating by Kaveri Pohlman, with a target price of 70. Despite the Buy call, shares fell from 16.77 to 16.77, challenging the optimistic stance.

ERAS

Buy

Mar 06, 2026

Target

$20.00

Current

$13.36

Performance

-13.64%

ERAS received a Buy rating from Kaveri Pohlman on Mar 06, 2026, aiming for 20. The rating hasn’t played out as hoped, with the stock trading 13.64% below expectations.

RAPT

Hold

Jan 20, 2026

Target

$58.00

Current

$58.01

Performance

0.76%

On Jan 20, 2026, Kaveri Pohlman published a Hold outlook on RAPT, with a target of 58. Sideways action left the Hold view intact, with no major move since 58.005.

JANX

Hold

Jan 20, 2026

Target

$12.00

Current

$14.05

Performance

6.84%

Kaveri Pohlman on Jan 20, 2026 assigned JANX a Hold rating, with a price target of 12. Shares outperformed expectations, climbing 6.84% despite the neutral view.

PALI

Buy

Dec 30, 2025

Target

$12.00

Current

$1.99

Performance

-15.68%

On Dec 30, 2025, Kaveri Pohlman reaffirmed PALI with a Buy rating, targeting 12. Shares slid 15.68% despite the recommendation, highlighting downside risks.

GPCR

Buy

Dec 09, 2025

Target

$99.00

Current

$56.15

Performance

-15.87%

GPCR was rated Buy by Kaveri Pohlman on Dec 09, 2025, with a price objective of 99. This case shows how bullish projections can fail, with the stock now below 56.15.

PVLA

Buy

Dec 05, 2025

Target

$200.00

Current

$120.80

Performance

20.21%

On Dec 05, 2025, Kaveri Pohlman initiated coverage on PVLA with a Buy rating and target of 200. The stock’s climb of 20.21% since the call highlights the foresight in the rating.

JBIO

Buy

Nov 25, 2025

Target

$25.00

Current

$13.97

Performance

11.40%

Kaveri Pohlman issued a Buy recommendation for JBIO on Nov 25, 2025, price target set at 25. Investors following the Buy call captured upside momentum, with shares now at 13.97.

TRVI

Buy

Nov 14, 2025

Target

$21.00

Current

$11.19

Performance

-1.58%

On Nov 14, 2025, TRVI was evaluated by Kaveri Pohlman, who gave a Buy rating and target of 21. So far, the Buy call awaits clearer momentum, with shares flat at 11.19.

ZURA

Buy

Nov 13, 2025

Target

$18.00

Current

$6.44

Performance

54.07%

Kaveri Pohlman rated ZURA as Buy on Nov 13, 2025, setting a price target of 18. The call has proven timely, with shares rising 54.07% toward the price target of 18.

SGMT

Buy

Oct 22, 2025

Target

$29.00

Current

$5.19

Performance

-30.34%

On Oct 22, 2025, SGMT was given a Buy rating by Kaveri Pohlman, with a target price of 29. Despite the Buy call, shares fell from 5.19 to 5.19, challenging the optimistic stance.

VTYX

Buy

Oct 01, 2025

Target

$11.00

Current

$14.00

Performance

288.89%

VTYX received a Buy rating from Kaveri Pohlman on Oct 01, 2025, aiming for 11. Momentum has favored the Buy call, with shares climbing from 14 to 14, rewarding those who trusted the recommendation.

ORKA

Buy

Sep 17, 2025

Target

$46.00

Current

$41.31

Performance

154.84%

On Sep 17, 2025, Kaveri Pohlman published a Buy outlook on ORKA, with a target of 46. Shares gained 154.84%, underscoring the accuracy of the bullish outlook toward 46.

AVBP

Buy

Jun 25, 2025

Target

$32.00

Current

$24.01

Performance

5.31%

Kaveri Pohlman on Jun 25, 2025 assigned AVBP a Buy rating, with a price target of 32. The Buy call aligned well with market performance, producing a gain of 5.31%.

MGNX

Hold

Aug 01, 2024

Target

—

Current

$3.08

Performance

-23.00%

On Aug 01, 2024, Kaveri Pohlman reaffirmed MGNX with a Neutral rating, targeting null. The Hold stance reflected market caution that was later justified.

GMAB

Buy

Jun 27, 2024

Target

$47.00

Current

$26.36

Performance

3.05%

GMAB was rated Buy by Kaveri Pohlman on Jun 27, 2024, with a price objective of 47. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

Frequency Asked Questions

Who is Kaveri Pohlman?

Kaveri Pohlman is an analyst from Clear Street specializing in the Healthcare sector.

What is Kaveri Pohlman's success rate?

Kaveri Pohlman currently has a success rate of +66.03%.

How many ratings has Kaveri Pohlman issued?

Kaveri Pohlman has issued 17 stock ratings so far.

What is the average return of Kaveri Pohlman's calls?

Their stock ratings have generated an average return of +58.82%.

What is Kaveri Pohlman's ranking?

Kaveri Pohlman is ranked #391 out of 4580 analysts.

What types of ratings does Kaveri Pohlman give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Kaveri Pohlman?

You can follow Kaveri Pohlman by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Kaveri Pohlman?

Their latest rating was a Buy on EVMN issued on 2026-03-18.